List of Excipients in Branded Drug KRINTAFEL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	KRINTAFEL	tafenoquine succinate	0173-0889	CELLULOSE, MICROCRYSTALLINE	1969-12-31
GlaxoSmithKline LLC	KRINTAFEL	tafenoquine succinate	0173-0889	FERRIC OXIDE RED	1969-12-31
GlaxoSmithKline LLC	KRINTAFEL	tafenoquine succinate	0173-0889	HYPROMELLOSE	1969-12-31
GlaxoSmithKline LLC	KRINTAFEL	tafenoquine succinate	0173-0889	MAGNESIUM STEARATE	1969-12-31

Krintafel Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Krintafel is the U.S. brand for tafenoquine succinate, a single-dose oral antimalarial approved by the FDA in 2018 for the radical cure, or prevention of relapse, of Plasmodium vivax malaria in patients aged 16 years and older. Its commercial value depends less on complex delivery technology than on dose size, tablet manufacturability, chemical stability, G6PD-related prescribing controls, and access to malaria procurement markets. The most credible excipient opportunities are generic substitution, improved tablet robustness, pediatric dosage forms, fixed-dose combinations, and formulations designed for tropical distribution. [1][2]

What excipients are used in Krintafel tablets?

Krintafel is supplied as a 300 mg tafenoquine tablet, administered as a single dose with food. The FDA labeling identifies the active ingredient as tafenoquine succinate and lists conventional tablet excipients, including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. The tablet is film-coated. [1][3]

Formulation element	Krintafel role	Commercial significance
Tafenoquine succinate	Active pharmaceutical ingredient	High dose load and salt-form control
Lactose monohydrate	Diluent and compression aid	Raises lactose-intolerance and excipient-equivalence questions
Microcrystalline cellulose	Filler and dry-binder	Supports tablet hardness and manufacturability
Croscarmellose sodium	Disintegrant	Helps achieve release from a large-dose tablet
Colloidal silicon dioxide	Glidant and moisture-control aid	Supports powder flow and content uniformity
Magnesium stearate	Lubricant	Controls ejection force but may affect wetting and dissolution
Film-coating system	Appearance, handling, and protection	Opportunity for differentiated moisture or taste protection

The formulation is conventional, but the 300 mg dose creates practical development constraints. A generic manufacturer must balance tablet size, mechanical strength, disintegration, dissolution, chemical stability, and acceptable excipient levels. A direct formulation copy is commercially attractive, but it may have limited differentiation unless it improves manufacturing yield, storage performance, or patient usability.

What excipient strategy is most relevant for tafenoquine?

The strongest strategy is to treat the excipient system as a performance and supply-chain tool rather than as a primary patent barrier.

Dose loading and tablet size

Tafenoquine tablets must deliver 300 mg of active drug in one administration. A formulation with excessive filler can produce a large tablet that is difficult to swallow and expensive to package. A high-load direct-compression design using microcrystalline cellulose, anhydrous dibasic calcium phosphate, coprocessed excipients, or spray-dried systems could reduce tablet volume.

The principal development risk is that replacing lactose with a higher-density filler may change dissolution, friability, hardness, and compression behavior. A generic product would need comparative dissolution data and, depending on the regulatory pathway, additional justification for formulation differences.

Moisture protection

Malaria products are distributed in regions with high heat and humidity. Excipient selection can improve stability by reducing moisture uptake and limiting hydrolytic or oxidative degradation. Relevant measures include:

• low-moisture diluents;
• optimized film coating;
• high-barrier blister packaging;
• desiccant-containing bottles;
• tighter control of water activity;
• excipient grades with controlled particle size and moisture content.

A moisture-control formulation could support a patent if the applicant claims a defined stability result tied to a specific excipient ratio, coating composition, packaging configuration, or manufacturing process. A broad claim that merely substitutes one conventional diluent for another would face a higher validity risk.

Dissolution and bioavailability

Tafenoquine has a high dose and is administered with food. The label states that food increases tafenoquine exposure, which is clinically relevant to product instructions and formulation development. [1] Excipient changes that alter wetting, disintegration, or dissolution could affect exposure.

Potential technologies include:

• surfactant-assisted wetting;
• particle-size engineering;
• amorphous solid dispersions;
• lipid-based formulations;
• wet granulation with controlled porosity;
• fast-disintegrating tablets.

These approaches may create a regulatory burden disproportionate to their value for an established tablet product. The best commercial target is usually a robust immediate-release tablet that matches the reference product rather than a complex reformulation requiring clinical bridging.

What formulations could be protected by new patents?

A defensible patent estate would likely focus on specific technical results.

Composition-of-matter and salt claims

Tafenoquine itself is an established active pharmaceutical ingredient. New composition-of-matter opportunities are therefore limited unless they concern:

• a previously unclaimed crystalline form;
• a specific polymorph;
• a hydrate or solvate;
• a particle-size distribution;
• a new salt with improved stability or processability;
• an amorphous or co-amorphous form.

Such claims require strong solid-state characterization and evidence that the claimed form is distinct and commercially relevant.

Tablet composition claims

Formulation patents could claim:

• a defined tafenoquine-to-excipient ratio;
• a high-drug-load tablet;
• a specific disintegrant system;
• a low-moisture formulation;
• a coating that improves stability;
• a dissolution profile;
• a tablet with improved mechanical strength;
• a formulation that reduces food-effect variability.

The most credible claims would link composition to a measurable result, such as a specified impurity level after accelerated storage, a dissolution range, or improved tablet friability.

Pediatric formulations

Krintafel is approved for patients aged 16 years and older. A lower-strength tablet, oral granule, dispersible tablet, or liquid formulation could address younger patients if clinical and regulatory requirements are met. [1]

Pediatric development presents a clear excipient opportunity because the adult 300 mg tablet is not easily divided into age-appropriate doses. Commercially relevant technologies include:

• taste-masked granules;
• oral suspension;
• sprinkle capsules;
• dispersible tablets;
• multiparticulate dosage forms;
• low-strength tablets for weight-based dosing.

Pediatric products would need careful control of excipient safety, dose uniformity, palatability, and stability after reconstitution. Taste masking may be difficult because tafenoquine is an aminoquinoline compound with potential bitterness.

When did Krintafel lose FDA exclusivity?

The FDA approved Krintafel on July 20, 2018. The product received five-year new chemical entity exclusivity, which generally ran through July 20, 2023, subject to FDA regulatory calculations and any applicable pediatric extension. [2][4]

Milestone	Date or status
FDA approval	July 20, 2018
NCE exclusivity	Generally expired in July 2023
Product type	Small-molecule oral tablet
Biosimilar pathway	Not applicable
Generic pathway	ANDA, subject to reference-product and patent requirements
Pediatric extension	Depends on FDA-recognized pediatric exclusivity status
Primary commercial issue	Patent and market demand, not biologic interchangeability

Expiration of NCE exclusivity does not eliminate patent barriers. A generic applicant must still evaluate listed patents, certification obligations, formulation differences, method-of-use claims, and potential 30-month litigation stays under the Hatch-Waxman framework.

What is the Orange Book status of Krintafel?

Krintafel is eligible for Orange Book listing because it is an FDA-approved small-molecule drug product. The relevant commercial question is whether current listed patents remain enforceable or create a viable Paragraph IV challenge.

An Orange Book review should assess:

1. listed formulation or composition patents;
2. method-of-use patents;
3. patent expiration dates;
4. pediatric exclusivity attached to listed patents;
5. delisting or expiration changes;
6. whether any patent claims read on an ANDA product;
7. whether the reference sponsor has submitted patent information under FDA requirements.

The FDA Orange Book, rather than commercial databases alone, is the controlling source for listed-patent status. [4] Patent families outside the Orange Book can still affect freedom to operate, particularly for crystalline forms, manufacturing processes, intermediates, particle engineering, and non-U.S. markets.

Are there Paragraph IV challenges or generic entry risks?

A tafenoquine generic would most likely proceed through an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence to the reference product. The product has several characteristics that may simplify generic development:

• immediate-release oral tablet;
• single active ingredient;
• conventional excipients;
• no biologic comparability requirement;
• no device-dependent administration;
• no complex extended-release mechanism.

The main risks are dose size, dissolution behavior, analytical method development, and the need to address the reference product's administration with food.

A Paragraph IV challenge could target listed patents covering the tablet, salt, formulation, or method of use. A generic applicant may also file a Paragraph III certification if it accepts a delayed launch date. If litigation follows a Paragraph IV notice, the reference sponsor may receive a statutory 30-month stay, subject to the timing and outcome of the litigation. [5]

No biosimilar risk exists because tafenoquine is a synthetic small molecule, not a biologic. The relevant threat is generic substitution.

What manufacturing and intellectual-property barriers affect Krintafel?

The largest manufacturing barriers are likely to be process consistency and supply economics rather than formulation complexity.

Active ingredient supply

Tafenoquine manufacturing may require control of:

• chiral purity;
• residual solvents;
• genotoxic or mutagenic impurities;
• polymorphic form;
• particle-size distribution;
• salt formation;
• residual metals;
• long-term chemical stability.

An alternative API supplier could gain commercial advantage through lower cost, reliable quality, regional production, or a protected process that reduces impurity formation.

Process patents

Process claims may cover:

• synthesis of tafenoquine intermediates;
• salt formation;
• crystallization;
• purification;
• particle-size reduction;
• granulation;
• coating;
• packaging.

Process patents are especially relevant in jurisdictions where product-by-process or manufacturing claims can delay local competition even when the final dosage form is conventional.

Excipient supply

Large-scale supply of pharmaceutical-grade lactose, microcrystalline cellulose, croscarmellose sodium, silicon dioxide, and magnesium stearate is generally available. The opportunity is not scarcity alone. It is qualification of alternative grades that provide better flow, lower moisture, improved compression, or more reliable regional supply.

How does Krintafel compare with competing antimalarial products?

Krintafel occupies a narrow position in the malaria market because it is used for radical cure or relapse prevention of P. vivax. It is not a universal replacement for artemisinin-based combination therapies, atovaquone/proguanil, chloroquine, or other antimalarials.

Product	Active ingredient	Primary role	Excipient opportunity
Krintafel	Tafenoquine	Single-dose P. vivax relapse prevention	High-load tablet, pediatric dosage form, stability
Primaquine	Primaquine phosphate	Relapse prevention	Lower-cost generic and pediatric formulation
Arakoda	Tafenoquine	Malaria prophylaxis	Regimen-specific formulation and packaging
Malarone	Atovaquone/proguanil	Treatment and prophylaxis	Pediatric suspension and fixed-dose manufacturing
Artemisinin combinations	Multiple actives	Treatment of uncomplicated malaria	Fixed-dose combination and dispersible tablets

Krintafel's main clinical distinction is single-dose administration, which can improve adherence compared with multi-day primaquine regimens. Its main commercial limitation is the requirement for G6PD testing because tafenoquine can cause hemolytic anemia in G6PD-deficient patients. [1]

What licensing deals and litigation affect Krintafel?

Tafenoquine originated from an antimalarial development program involving the U.S. government, the Walter Reed Army Institute of Research, and GlaxoSmithKline. GSK commercialized Krintafel in the United States and Arakoda for prophylaxis. [2][6]

The commercial structure is therefore more relevant to licensing and public-health access than to consumer pharmaceutical marketing. Procurement agencies, military channels, travel-medicine providers, and endemic-country health systems are potential customers.

No major public patent settlement is established in the cited sources. A definitive litigation assessment requires review of current FDA, PACER, and patent records. The practical exposure remains dependent on Orange Book listings, ANDA filings, and the commercial willingness of generic manufacturers to enter a relatively specialized malaria market.

What commercial opportunities exist for Krintafel excipients?

The highest-value opportunities are:

1. A lower-cost direct-compression platform with equivalent dissolution.
2. A moisture-resistant tablet for tropical distribution.
3. A pediatric formulation for patients below the current labeled age.
4. A taste-masked dispersible or granule product.
5. A dual-source excipient package that reduces supply-chain risk.
6. A blister-pack configuration optimized for single-dose administration.
7. A fixed-dose or co-packaged malaria regimen supporting adherence.
8. A 505(b)(2) reformulation with a clinically meaningful dosing or administration advantage.

The commercial case for a new formulation is strongest when it solves a defined access problem. A minor excipient swap without measurable clinical, stability, manufacturing, or cost benefit is unlikely to support premium pricing or a durable patent position.

Key Takeaways

• Krintafel is a 300 mg tafenoquine succinate tablet with a conventional excipient platform.
• The primary listed excipients include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate.
• NCE exclusivity generally expired in July 2023, but patent and regulatory barriers must be reviewed separately.
• Krintafel faces generic rather than biosimilar competition.
• The strongest excipient opportunities involve moisture protection, high-dose tablet engineering, pediatric delivery, taste masking, and supply-chain resilience.
• Patentable value is more likely to arise from measurable performance improvements than from routine excipient substitution.
• Market access depends on malaria procurement economics, G6PD testing requirements, and the relatively narrow P. vivax indication.

FAQs

Can tafenoquine be formulated as a liquid suspension?

Yes, but a liquid or reconstituted suspension would require evaluation of chemical stability, sedimentation, dose uniformity, palatability, preservative compatibility, and packaging. It would be most commercially relevant for pediatric use.

Is lactose-free Krintafel a realistic generic opportunity?

Yes. A lactose-free formulation could replace lactose monohydrate with an alternative diluent, but the applicant would need to demonstrate equivalent performance and control changes in tablet compression, disintegration, dissolution, and stability.

Could a generic manufacturer sell tafenoquine in a smaller tablet?

Possibly. A smaller tablet would require higher drug loading, denser excipients, or a different manufacturing process. The product would still need to satisfy applicable pharmaceutical equivalence and bioequivalence requirements.

Does G6PD testing create a formulation patent opportunity?

Not by itself. G6PD testing is a clinical and regulatory requirement tied to safety. A formulation patent would need to claim a distinct dosage form, dosing approach, or delivery system with technical support.

Is a fixed-dose combination with tafenoquine commercially attractive?

Potentially, but the clinical role must be clear. A combination could simplify malaria treatment or relapse prevention, yet it would face compatibility, dose-ratio, regulatory, clinical, and market-access requirements.

References

1. U.S. Food and Drug Administration. (2023). Krintafel (tafenoquine) prescribing information.
2. U.S. Food and Drug Administration. (2018, July 20). FDA approves new drug for malaria.
3. National Library of Medicine. (2024). Krintafel- tafenoquine succinate tablet, film coated. DailyMed.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2023). ANDA submissions: Amendments and requests for final approval to tentatively approved ANDAs.
6. GlaxoSmithKline plc. (2018). Annual report 2018.